SCHEMBL5544653

SCHEMBL5544653

CC(=O)Nc1ccc(C(F)(F)C(F)(F)F)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.71
HTT P42858 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MAPK1 P28482 1/20 0.54
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 1/20 0.53
BRD4 O60885 1/20 0.53
NR1I2 O75469 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MB P02144 1/20 0.53
CYP1A1 P04798 1/20 0.53
CA3 P07451 1/20 0.53
CYP3A4 P08684 1/20 0.53
RARG P13631 1/20 0.53
TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28028708 0.85 SMN1; SMN2 (0.71) SMN1; SMN2HTTL3MBTL1MAPK1KMT2A
SCHEMBL9784355 0.85 SMN1; SMN2 (0.71) SMN1; SMN2HTTL3MBTL1MAPK1KMT2A
SCHEMBL14546864 0.85 SMN1; SMN2 (0.71) SMN1; SMN2HTTL3MBTL1MAPK1KMT2A
SCHEMBL669442 0.84 EPHX2 (0.70) SMN1; SMN2HTTL3MBTL1MAPK1KMT2A
SCHEMBL2081375 0.83 SMN1; SMN2 (1.00) SMN1; SMN2HTTL3MBTL1MAPK1TDP1
SCHEMBL2096237 0.82 EPHX2 (0.52) SMN1; SMN2L3MBTL1RAB9AEPHX2KIF11
SCHEMBL2096233 0.82 EPHX2 (0.52) SMN1; SMN2HTTMAPK1KMT2AMEN1
SCHEMBL16349508 0.82 SMN1; SMN2 (0.68) SMN1; SMN2HTTL3MBTL1MAPK1KMT2A
SCHEMBL21047664 0.81 SMN1; SMN2 (0.72) SMN1; SMN2HTTL3MBTL1MAPK1KMT2A
SCHEMBL2094035 0.81 SMN1; SMN2 (0.56) SMN1; SMN2HTTMAPK1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2881386-B1 AMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2018-03-07 EP disclosed
US-9185910-B2 Amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-17 US disclosed
US-20150189880-A1 AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-07-09 US disclosed
EP-2881386-A1 AMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2015-06-10 EP disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885HTT 4644/4885L3MBTL1 1931/4885
US-20150189880-A1 AMIDE COMPOUND H1-3, H1-0, H1-4 SMN1; SMN2 2598/4885HTT 2431/4885L3MBTL1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.